450 results on '"Ugolini, Clara"'
Search Results
102. HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer
103. Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation
104. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
105. MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis?
106. MON-495 Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma
107. Digital Gene Expression Analysis on Cytology Smears Can Rule Out Malignancy in Follicular-Patterned Thyroid Tumors
108. Synchronous squamous cell carcinoma and papillary thyroid carcinoma arising from the thyroglossal duct remnant: Case report and a review of the literature
109. The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy
110. Functional Characterization of the Novel T599I-VKSRdel BRAF Mutation in a Follicular Variant Papillary Thyroid Carcinoma
111. BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study
112. Characterization of Thyroglobulin Epitopes in Patients with Autoimmune and Non-Autoimmune Thyroid Diseases Using Recombinant Human Monoclonal Thyroglobulin Autoantibodies
113. Down-regulation of miR-7-5pand miR-548ar-5ppredicts malignancy in indeterminate thyroid nodules negative for BRAFand RASmutations
114. A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion
115. Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma
116. The Heterogeneous Distribution of BRAF Mutation Supports the Independent Clonal Origin of Distinct Tumor Foci in Multifocal Papillary Thyroid Carcinoma
117. Identification of a Novel Point Mutation in the RET Gene (Ala883Thr), Which Is Associated with Medullary Thyroid Carcinoma Phenotype Only in Homozygous Condition
118. Downregulation of FUCA-1 (alpha.LFucosidase-1) in human thyroid anaplastic carcinomas..... Europ. Thyroid Journal, vol 3 suppl.1, 2014, Poster #306 page 199
119. Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: an ATC-like and a PDTC-like
120. Junctional adhesion molecule-A is down-regulated in anaplastic thyroid carcinomas and reduces cancer cell aggressiveness by modulating p53 and GSK3 α/β pathways
121. A microRNA signature for the differential diagnosis of salivary gland tumors
122. Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO
123. Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases
124. Identification of two distinct molecular subtypes by digital RNA counting of 'non-invasive follicular tumour with papillary-like nuclear features (NIFTP)'
125. BRAF(K601E) Mutation in a Follicular Thyroid Adenoma
126. Abstract 5402: A panel of miRNAs for diagnosis of wild-type thyroid nodules with pre-surgical indeterminate cytology
127. The immune-profile of mismatch repair deficient (dMMR) colorectal cancers (CRCs) differs according to primary tumor sidedness.
128. Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience
129. Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma
130. RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
131. A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma
132. A dual mechanism of activation of the Sonic Hedgehog pathway in anaplastic thyroid cancer: crosstalk with RAS-BRAF-MEK pathway and ligand secretion by tumor stroma
133. Differences in miRNA expression profiles between wild-type and mutated NIFTPs
134. Identification of Two Distinct Molecular Subtypes of Non-Invasive Follicular Neoplasm with Papillary-Like Nuclear Features by Digital RNA Counting
135. Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer
136. Mediastinal dedifferentiated liposarcoma
137. Significant difference between the prevalence of C cell hyperplasia (CCH) in benign thyroid nodules without histological thyroiditis (HT) and in papillary/follicular thyroid cancers (PTC/FTC) at histology
138. Humanα-L-fucosidase-1attenuates the invasive properties of thyroid cancer
139. BRAFK601E Mutation in a Follicular Thyroid Adenoma: A Case Report
140. Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis
141. Whole Exome Sequencing of Medullary Thyroid Carcinomas did not identify oncogenic drivers alternative to RET and RAS genes
142. SIMULTANEOUS MEDULLARY AND PAPILLARY THYROID CARCINOMAS SHOW INDEPENDENT GENETIC ORIGIN
143. I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE
144. TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells
145. New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with doubleRETmutations
146. ‘Incidental’ and ‘non-incidental’ thyroid papillary microcarcinomas are two different entities
147. Downregulation of Alpha‐L‐Fucosidase Expression Is Related to Dedifferentiation and Worse Prognosis in Thyroid and Breast Cancer.
148. Genetic heterogeneity of medullary thyroid carcinoma
149. L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE
150. Differential expression of RETisoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.